Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

4D MOLECULAR THERAPEUTICS, INC.

(FDMT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

4D MOLECULAR THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)

08/12/2021 | 04:19pm EDT

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2021, 4D Molecular Therapeutics, Inc. ("4DMT") announced its unaudited financial results for the quarter ended June 30, 2021. A copy of 4DMT's press release, titled "4D Molecular Therapeutics Reports Financial Results for the Second Quarter of 2021 and Provides Operational Highlights," is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.



Exhibit
Number                                  Description
99.1        Press Release, dated August 12, 2021 titled "4D Molecular Therapeutics
          Reports Financial Results for the Second Quarter of 2021 and Provides
          Operational Highlights"
104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document)


                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about 4D MOLECULAR THERAPEUTICS, INC.
04:03p4D MOLECULAR THERAPEUTICS : Reports Interim Results from the 4D-310 Phase 1/2 Clinical Tri..
AQ
09:32aINSIDER SELL : 4d Molecular Therapeutics
MT
10/134D MOLECULAR THERAPEUTICS INC. : Other Events (form 8-K)
AQ
10/114D MOLECULAR THERAPEUTICS' : 4D-125 Drug Shows Potential in Eye Disease Trial
MT
10/104D MOLECULAR THERAPEUTICS : ASRS 2021 Annual Meeting – 4D-125 for XLRP Phase 1/2 Cli..
PU
10/104D MOLECULAR THERAPEUTICS : Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cli..
AQ
10/104D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Cl..
CI
10/06Health Care Stocks Trade Lower Premarket Wednesday
MT
10/064D MOLECULAR THERAPEUTICS : Obtains FDA Clearance for Phase 1/2 Trial of Wet Age-Related M..
MT
10/064D MOLECULAR THERAPEUTICS : Announces FDA Clearance of IND Application for 4D-710, an A101..
AQ
More news
Analyst Recommendations on 4D MOLECULAR THERAPEUTICS, INC.
More recommendations